WO2002093152A1 - Method for the determination of glycated hemoglobin - Google Patents
Method for the determination of glycated hemoglobin Download PDFInfo
- Publication number
- WO2002093152A1 WO2002093152A1 PCT/US2002/015706 US0215706W WO02093152A1 WO 2002093152 A1 WO2002093152 A1 WO 2002093152A1 US 0215706 W US0215706 W US 0215706W WO 02093152 A1 WO02093152 A1 WO 02093152A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hemoglobin
- sample
- amount
- determining
- glycated hemoglobin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F01—MACHINES OR ENGINES IN GENERAL; ENGINE PLANTS IN GENERAL; STEAM ENGINES
- F01B—MACHINES OR ENGINES, IN GENERAL OR OF POSITIVE-DISPLACEMENT TYPE, e.g. STEAM ENGINES
- F01B1/00—Reciprocating-piston machines or engines characterised by number or relative disposition of cylinders or by being built-up from separate cylinder-crankcase elements
- F01B1/12—Separate cylinder-crankcase elements coupled together to form a unit
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F01—MACHINES OR ENGINES IN GENERAL; ENGINE PLANTS IN GENERAL; STEAM ENGINES
- F01L—CYCLICALLY OPERATING VALVES FOR MACHINES OR ENGINES
- F01L9/00—Valve-gear or valve arrangements actuated non-mechanically
- F01L9/20—Valve-gear or valve arrangements actuated non-mechanically by electric means
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F02—COMBUSTION ENGINES; HOT-GAS OR COMBUSTION-PRODUCT ENGINE PLANTS
- F02B—INTERNAL-COMBUSTION PISTON ENGINES; COMBUSTION ENGINES IN GENERAL
- F02B75/00—Other engines
- F02B75/16—Engines characterised by number of cylinders, e.g. single-cylinder engines
- F02B75/18—Multi-cylinder engines
- F02B75/20—Multi-cylinder engines with cylinders all in one line
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/721—Haemoglobin
- G01N33/723—Glycosylated haemoglobin
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01M—PROCESSES OR MEANS, e.g. BATTERIES, FOR THE DIRECT CONVERSION OF CHEMICAL ENERGY INTO ELECTRICAL ENERGY
- H01M8/00—Fuel cells; Manufacture thereof
- H01M8/16—Biochemical fuel cells, i.e. cells in which microorganisms function as catalysts
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/795—Porphyrin- or corrin-ring-containing peptides
- G01N2333/805—Haemoglobins; Myoglobins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
- Y02E60/30—Hydrogen technology
- Y02E60/50—Fuel cells
Definitions
- the present invention relates to a process for the determination of the amount of irreversibly glycated hemoglobin, or HbAlc, present in a sample of blood, relative to the amount of total hemoglobin.
- the invention incorporates in the method an electrochemical, enzyme-catalyzed reaction or reactions.
- Hb Al c is a glycated hemoglobin formed by a binding reaction between an amine group of hemoglobin and the glucose aldehyde group, for example between the amino group of the N-terminal valine of the ⁇ -chain of hemoglobin and the glucose aldehyde group.
- the binding reaction first forms a Schiff s base and then a stable ketoamine by Amadori rearrangement.
- the percentage of HbAlc i.e. the amount of glycated hemoglobin relative to total hemaglobin in the blood
- percentage HbAlc has become an important measurement by which health care providers can assist diabetic patients in their care.
- HbAlc assays There are many known assays that can be used to determine Hb Al c percentage. In recent years research efforts have focused on creating assays that are both highly accurate and fast. However, known HbAlc assays typically require a substantial number of time-consuming steps wherein the blood components must be separated and treated. [0006] hi the health care context, a diabetic patient is typically guided by a physician to obtain an HbAlc measurement when the physician realizes that there is a need for such information during an office visit. The patient then provides a blood sample to a laboratory and results are returned to the physician hours or days later. Typically, the lab will use a table top analyzer of the type presently available commercially. This time lag between the patient's visit and the result of the test requires that the physician review the result long after the patient has left the office. If the physician believes that further consultation with the patient is required in light of the test result, the patient must be contacted again.
- the present invention comprises a method of determining the amount or percentage of glycated hemoglobin in blood or a sample derived from blood, in which at least one of the assay steps is performed electrochemically.
- the use of electrochemical methodology can retain or improve the accuracy of other methods and potentially speed the ultimate determination.
- Devices providing electrochemical measurements can also be relatively small.
- the method includes electrochemically determining the total amount of hemoglobin in a sample by electrochemically measuring, in an oxygen electroreduction reaction at a cathode, the amount of oxygen in the sample, preferably after it was exposed to air so as to assure that the hemoglobin is oxygenated. Because the amount of oxygen dissolved in aerated physiological buffer at the assay temperature in the absence of hemoglobin, termed here free oxygen, is known, the total hemoglobin may be determined by subtracting the amount of free oxygen from the total oxygen measured, recognizing the fast equilibrium Hb + O 2 ⁇ HbO 2 .
- Electrochemically determining the total hemoglobin value can be followed by a determination of the amount of glycated hemoglobin in the sample, hi the process of the invention, the cathode reaction is accomplished by contacting the sample with an enzyme.
- the enzyme can be a copper-containing enzyme, containing four copper ions per active unit.
- the family of these enzymes includes, for example, laccases and bilirubin oxidases.
- the glycated hemoglobin can be determined in different ways.
- the glycated hemoglobin is separated from the sample, for example by capturing it with immobilized antibodies against HbAlc or with a boronic acid modified surface. Examples of surfaces include those of small magnetic, polymer or glass beads.
- the percentage HbAlc can then be determined by either measuring the hemoglobin left in the sample from which the HbAlc has been removed, or by measuring the amount of glycated hemoglobin in the separated portion of the sample.
- the amount of glycated hemoglobin can be measured spectrophotometrically, or by an electrochemical measurement in the same manner as the total hemoglobin.
- the hemoglobin is hydrolyzed by an established method, such as digestion with a proteolytic enzyme.
- the ketoamines in the hydrolyzate such as the fragments comprising the Amadori rearrangement products of the Schiff base formed of amino acids, including valine and glucose, are then determined, preferably by an electrochemical method.
- the electrooxidation of the hydrolyzed Amadori rearrangement product may be catalyzed by an enzyme and a dissolved or immobilized redox mediator.
- the enzyme can be, for example, a fructosamine oxidase, a four copper-ion containing copper enzyme such as a laccase or a bilirubin oxidase, ceruloplasmin, or ascorbate oxidase.
- the redox mediators can be, for example, complexes of Os 2+ 3+ , or of Ru 2+ 3+ .
- the invention incorporates one or more electrochemical steps in the method of determining percentage HbAlc.
- the method of the invention is based on the understanding that hemoglobin, being the oxygen carrier of blood, reversibly binds oxygen, forming HbO 2 .
- the equilibrium Hb + O 2 ⁇ HbO 2 is rapid. Because O 2 is rapidly released by HbO 2 when O 2 is depleted from the solution in an electrochemical cell, it is possible to determine the concentration of HbO 2 in light of the reaction 4H + + 4e " + HbO 2 ⁇ 2 H 2 O + Hb.
- the cell membranes may be ruptured by exposing them to de-ionized water or a detergent. In this manner, the dissolved hemoglobin will pass the filtration membrane. The cell membranes will remain on the filter paper.
- total hemoglobin is then determined from the sample by electroreducing the oxygen bound to the hemoglobin to water at the cathode in an electrochemical cell.
- the oxygen electroreduction catalyst preferably comprises a so-called "copper” enzyme such as bilirubin oxidase, a laccase, or an ascorbate oxidase.
- the catalyst may further comprise a redox mediator to form a "wired enzyme" arrangement.
- the electrical connection is between a cathode of the electrochemical cell and the oxygen reduction catalyzing enzyme, especially a copper-containing enzyme, such as bilirubin oxidase (sometimes referenced herein as BOD).
- a copper-containing enzyme such as bilirubin oxidase (sometimes referenced herein as BOD).
- BOD bilirubin oxidase
- Bilirubin oxidase catalyzes the four- electron reduction of oxygen to water.
- a cathode constructed with bilirubin oxidase is especially preferred as the redox enzyme can function under relatively neutral pH conditions.
- other enzymes e.g. lacasse
- the concentration of HbO 2 can be measured by the reaction 4H “ + 4e " + HbO 2 - ⁇ 2 H 2 O + Hb. This measurement may be done coulometrically.
- the concentration of available oxygen in arterial blood tends to be about 8 mM. Because the concentration of O in water in equilibrium with air at 25°C is known (the concentration is generally around 0.24 mM), the amount of non-Hb bound O can then be subtracted in calculating the amount of HbO 2 .
- a cathode useful in the invention effectuates the four-electron electroreduction of O to water.
- the blue, copper-containing oxidases examples of which include laccases, ascorbate oxidase, ceruloplasmine, and bilirubin oxidase, catalyze the four-electron reduction of O to water.
- the preferred enzymes are exemplified by bilirubin oxidases, which unlike laccases, retain their more than 80%, and usually retain more than 90%, of the maximal activity under physiological pH.
- the catalytic reduction of O 2 to water depends on the coordination of the four Cu + 2+ ions of the enzymes.
- Type 1 Cu + 2+ centers show an intense Cys S to Cu(2) charge transfer band at around 600 nm; the site accepts electrons from an organic substrate, such as a phenol, ascorbate, or bilirubin, and relays the electrons to the O 2 - reduction site.
- the O 2 -reduction site is a tri-nuclear cluster, consisting of one type 2 Cu + 2+ center and a pair of type 3 Cu + 2+ centers, their spectrum showing a shoulder at 330 nm.
- bilirubin oxidase there are different forms of bilirubin oxidase available, such as bilirubin oxidase from Myrothecium verrucaria (Mv- OD) and bilirubin oxidase from Mv- OD.
- Mv- OD Myrothecium verrucaria
- bilirubin oxidase from Myrothecium verrucaria
- Tt-BOD Trachyderma tsunodae
- Bilirubin oxidases are usually monomeric proteins and have molecular weights approximately ranging from about 52 kDa to about 65 kDa.
- Tt-BOD is a monomeric protein with a molecular weight of approximately 64 kDa, while that of v-BOD is about 52 kDa.
- Both v-BOD and Tt-BOD are multicopper oxidases, each containing one type 1, one type 2, and two type 3 copper ions. These three types are defined by their optical and magnetic properties. Type 1
- (blue) copper ions have a characteristic Cys to Cu (2) charge-transfer band near 600 nm.
- the type 1 copper center accepts electrons from the electron-donating substrate of the enzyme and relays these to the O 2 reduction site.
- the latter is a trinuclear cluster, consisting of a type 2 copper ion and a type 3 pair of cupric ions with a characteristic 330 nm shoulder in its absorption spectrum.
- bilirubin oxidase from Myrothecium verrucaria could be used in a cathode electrocatalyst layer.
- a cathode constructed using v-BOD the electrostatic adduct of the poly-anionic Mv-BOD and its "wire", the polycationic redox copolymer of polyacrylamide (PAA) and poly (N- vinylimidazole) (PVI) complexed with [Os (4,4'-dichloro-2,2'-bipyridine) 2 Cl] +/2+ , are immobilized on the cathode.
- PAA polyacrylamide
- PVI poly (N- vinylimidazole)
- bilirubin oxidase (BOD) from Trachyderma tsunodae can be used in a cathode electrocatalyst layer.
- Tt-BOD all of the ligands of the Type 2 and Type 3 Cu +/2+ centers are His (histidines), similar to ascorbate oxidase. It is believed that the full histidine coordination of the type 2 Cu +/2+ center is the underlying cause of the relative insensitivity of bilirubin oxidases to inhibition by the chloride and hydroxide anions (as are found at physiological concentration). Accordingly, it is expected that other enzymes having the three types of copper centers would also be useful as components of cathode electrocatalysts in cathodes operating under at near neutral pH.
- Redox polymers for use in the method may include PAA-PVI-[Os(4,4'-dichloro-2,2'-bipyridine) 2 Cl] +/2+ which can be prepared as follows: 4,4'-Dinitro-2,2'-bipyridine N,N -dioxide was prepared as described in Anderson, S.; Constable, E. C; Seddon, K. R.; Turp, E. T.; Baggott, J. E.; Pilling, J. J. Chem. Soc, Dalton Trans.
- Os(dcl-bpy) 2 Cl 2 was prepared as follows: (NH 4 ) OsCl 6 and "dcl-bpy were dissolved in ethylene glycol in a 1 :2 molar ratio and refluxed under argon for 1 hour (yield 85%). The Os(dcl-bpy) 2 Cl 2 was then complexed with the 1 :7 polyacrylarnide-poly(N- vinylimidazole) (PAA-PVI) copolymer and purified as described in Zakeeruddin, S. M.; D. M. Fraser, D. M.; Nazeeruddin, M.-K.; Gratzel, M. J. Electroanal. Chem.
- the HbAlc/Hb ratio can be determined by separating the HbAlc fraction from the sample.
- the HbAlc which can be converted to HbAlcO2
- these fructosyl amines may be subject to direct enzyme catalyzed electro-oxidation, for example using fructosyl amine oxidases having FAD/FADH reaction centers, or by one of the copper enzymes.
- Example 1 Affinity gel columns can be used to separate bound, glycosylated hemoglobin from the nonglycosylated fraction.
- the gel contains immobilized -aminophenylboronic acid on cross-linked, beaded agarose.
- the boronic acid first reacts with the cis-dio ⁇ groups of glucose bound to hemoglobin to form a reversible 5-membered ring complex, thus selectively holding the glycosylated hemoglobin on the column.
- the nonglycosylated hemoglobin is eluted.
- the ring complex is then dissociated by sorbitol, which permits elution of the glycosylated hemoglobin.
- affinity chromatography absorbances of the bound and nonbound fractions, measured at 415 nm, are used to calculate the percent of glycosylated hemoglobin.
- Example 2 Magnetic beads that are ⁇ 1 ⁇ m (available from Bangs Laboratories), on which antibodies against HbAlc would be immobilized, can be mixed with a citrate-solution diluted blood sample. Two measurements are performed, one on the entire sample, and a second on the re-oxygenated Hbl Ac bound to the magnetic beads, after their removal to a chamber of an electrochemical cell. Alternatively, the second measurement can be on the residual Hb, after the magnetic separation of the bead-bound HbAlc.
- Example 3 Two samples of the lysed red blood cells in citrate buffer can be coulometrically assayed in two chambers, hi Chamber 1, the total HbO 2 would be measured. Chamber 2 contains the immobilized HbAlc-specific antibody. Either of the two would capture HbAlc without capturing Hb. After rinsing or passage of citrate buffer through Chamber 2 (e.g. by repeated filling through capillary action and touching the edge of the chamber to filter paper), the chamber would contain only HbAlcO 2 .
- the HbAlcO 2 would be assayed electrochemically (preferably coulometrically) by its electroreduction, 4H + + 4e " + HbAlcO 2 ⁇ 2 H 2 O + HbAlc.
- the HbAlc/Hb ratio can then be calculated from the two coulometric measurements.
- Example 4 As in example 3 above, except that the two coulometric measurements would be performed in a single chamber.
- the chamber which would contain the immobilized HbAlc capture agent, would be filled with a citrate solution of the lysed red blood cells.
- the total HbO 2 would be electrochemically (preferably coulometrically) measured.
- the unbound Hb, but not the bound HbAlc would be rinsed out, the HbAlc would be re-equilibrated with air, and its amount would be coulometrically measured.
- the assay of the invention in one form, can comprise a method of determining the ratio of HbAlc to total Hb in blood, the method comprising obtaining a blood sample; electrochemically determining the total amount of hemoglobin in the sample, or in a treated portion of the sample; electrochemically determining the amount of HbAlc in the sample; and calculating the ratio of HbAlc to total hemoglobin.
- the method of electrochemically determining the total amount of hemoglobin in the sample is accomplished by placing the sample in an electrochemical cell in which, at the cathode, a cathode enzyme is bound, for example using a redox polymer.
- the enzyme be a laccase or a bilirubin oxidase which will electroreduce oxygen bound to the hemoglobin to water.
- the hemoglobin content is determined from the oxygen content.
- the electrochemical determination of HbAlc fraction can be accomplished by one of two methods.
- the Ale containing fraction of the hemoglobin is separated by physical means, such as by use of an HbAlc specific antibody.
- the HbAlc then present in the form of HbAlcO 2 can then be electrochemically determined by electroreduction of the oxygen (again with an enzyme selected to accomplish the four electron reduction of oxygen).
- the glycated protein a fructosyl amine
- the glycated protein can be directly oxidized on cross-linked poly(N-vinyl imidazole) based redox polymer films (without an enzyme) of sufficiently positive oxidizing potential.
- enzymatic electrooxidation of the fructosyl amines can be used for this part of the determination.
- the invention comprises an electrochemical method for the determination of HbAlc (or HbAlc/Hb ratio) comprising determining from a starting sample, in an electrochemical cell, the total amount of hemoglobin (e.g. by measuring bound oxygen), separating the HbAlc component from the sample using an HbAlc capturing agent, and measuring hemoglobin content in the captured or non-captured portion of the sample.
- Devices for accomplishing the method of the invention are preferably small.
- biosensor strips which include a cathode at which the chemistry discussed herein is placed, as well at which the necessary anode is constructed.
- Such strips can be prepared using techniques presently used for making commercially available biosensor strips that are used for glucose determinations, such as the FreeStyle blood glucose system sold by TheraSense, Inc. Samples could then be applied to these strips and the strips placed in the measuring instrument (meter) to be "read.”
- the electrochemical method of the invention provides a significant potential advantage of creating a smaller analysis device while providing accurate results.
Abstract
Description
Claims
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29136101P | 2001-05-16 | 2001-05-16 | |
US60/291,361 | 2001-05-16 | ||
US37788602P | 2002-05-02 | 2002-05-02 | |
US60/377,886 | 2002-05-02 | ||
US10/146,577 US7005273B2 (en) | 2001-05-16 | 2002-05-14 | Method for the determination of glycated hemoglobin |
US10/146,577 | 2002-05-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002093152A1 true WO2002093152A1 (en) | 2002-11-21 |
Family
ID=27386420
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/015706 WO2002093152A1 (en) | 2001-05-16 | 2002-05-15 | Method for the determination of glycated hemoglobin |
Country Status (2)
Country | Link |
---|---|
US (3) | US7005273B2 (en) |
WO (1) | WO2002093152A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0526752A (en) * | 1991-07-16 | 1993-02-02 | Oval Corp | Manufacture of pressure sensor |
JP2014523235A (en) * | 2011-05-24 | 2014-09-11 | サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィク | Bilirubin oxidase from rice blast fungus and use thereof |
US9410915B2 (en) | 2004-06-18 | 2016-08-09 | Roche Operations Ltd. | System and method for quality assurance of a biosensor test strip |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6036924A (en) | 1997-12-04 | 2000-03-14 | Hewlett-Packard Company | Cassette of lancet cartridges for sampling blood |
US6391005B1 (en) | 1998-03-30 | 2002-05-21 | Agilent Technologies, Inc. | Apparatus and method for penetration with shaft having a sensor for sensing penetration depth |
US6294281B1 (en) * | 1998-06-17 | 2001-09-25 | Therasense, Inc. | Biological fuel cell and method |
JPWO2002022698A1 (en) * | 2000-09-12 | 2004-01-22 | 早出 広司 | Enzyme mimetic polymer |
US8641644B2 (en) | 2000-11-21 | 2014-02-04 | Sanofi-Aventis Deutschland Gmbh | Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means |
US7005273B2 (en) * | 2001-05-16 | 2006-02-28 | Therasense, Inc. | Method for the determination of glycated hemoglobin |
US8337419B2 (en) | 2002-04-19 | 2012-12-25 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
EP1404234B1 (en) | 2001-06-12 | 2011-02-09 | Pelikan Technologies Inc. | Apparatus for improving success rate of blood yield from a fingerstick |
US7749174B2 (en) | 2001-06-12 | 2010-07-06 | Pelikan Technologies, Inc. | Method and apparatus for lancet launching device intergrated onto a blood-sampling cartridge |
US7682318B2 (en) | 2001-06-12 | 2010-03-23 | Pelikan Technologies, Inc. | Blood sampling apparatus and method |
US7981056B2 (en) | 2002-04-19 | 2011-07-19 | Pelikan Technologies, Inc. | Methods and apparatus for lancet actuation |
US9427532B2 (en) | 2001-06-12 | 2016-08-30 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US9226699B2 (en) | 2002-04-19 | 2016-01-05 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling module with a continuous compression tissue interface surface |
ATE485766T1 (en) | 2001-06-12 | 2010-11-15 | Pelikan Technologies Inc | ELECTRICAL ACTUATING ELEMENT FOR A LANCET |
US9795747B2 (en) | 2010-06-02 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Methods and apparatus for lancet actuation |
US7025774B2 (en) | 2001-06-12 | 2006-04-11 | Pelikan Technologies, Inc. | Tissue penetration device |
DE60234598D1 (en) | 2001-06-12 | 2010-01-14 | Pelikan Technologies Inc | SELF-OPTIMIZING LANZET DEVICE WITH ADAPTANT FOR TEMPORAL FLUCTUATIONS OF SKIN PROPERTIES |
US8267870B2 (en) | 2002-04-19 | 2012-09-18 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for body fluid sampling with hybrid actuation |
US7232451B2 (en) | 2002-04-19 | 2007-06-19 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7175642B2 (en) | 2002-04-19 | 2007-02-13 | Pelikan Technologies, Inc. | Methods and apparatus for lancet actuation |
US9248267B2 (en) | 2002-04-19 | 2016-02-02 | Sanofi-Aventis Deustchland Gmbh | Tissue penetration device |
US7297122B2 (en) | 2002-04-19 | 2007-11-20 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7717863B2 (en) | 2002-04-19 | 2010-05-18 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7674232B2 (en) | 2002-04-19 | 2010-03-09 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7547287B2 (en) | 2002-04-19 | 2009-06-16 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7226461B2 (en) | 2002-04-19 | 2007-06-05 | Pelikan Technologies, Inc. | Method and apparatus for a multi-use body fluid sampling device with sterility barrier release |
US7892183B2 (en) | 2002-04-19 | 2011-02-22 | Pelikan Technologies, Inc. | Method and apparatus for body fluid sampling and analyte sensing |
US8702624B2 (en) | 2006-09-29 | 2014-04-22 | Sanofi-Aventis Deutschland Gmbh | Analyte measurement device with a single shot actuator |
US8784335B2 (en) | 2002-04-19 | 2014-07-22 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling device with a capacitive sensor |
US9314194B2 (en) | 2002-04-19 | 2016-04-19 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US7648468B2 (en) | 2002-04-19 | 2010-01-19 | Pelikon Technologies, Inc. | Method and apparatus for penetrating tissue |
US7291117B2 (en) | 2002-04-19 | 2007-11-06 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8579831B2 (en) | 2002-04-19 | 2013-11-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US7229458B2 (en) | 2002-04-19 | 2007-06-12 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7909778B2 (en) | 2002-04-19 | 2011-03-22 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8221334B2 (en) | 2002-04-19 | 2012-07-17 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US7491178B2 (en) | 2002-04-19 | 2009-02-17 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7371247B2 (en) | 2002-04-19 | 2008-05-13 | Pelikan Technologies, Inc | Method and apparatus for penetrating tissue |
US7976476B2 (en) | 2002-04-19 | 2011-07-12 | Pelikan Technologies, Inc. | Device and method for variable speed lancet |
US9795334B2 (en) | 2002-04-19 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US7901362B2 (en) | 2002-04-19 | 2011-03-08 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7331931B2 (en) | 2002-04-19 | 2008-02-19 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7368190B2 (en) * | 2002-05-02 | 2008-05-06 | Abbott Diabetes Care Inc. | Miniature biological fuel cell that is operational under physiological conditions, and associated devices and methods |
US8574895B2 (en) | 2002-12-30 | 2013-11-05 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus using optical techniques to measure analyte levels |
DK1633235T3 (en) | 2003-06-06 | 2014-08-18 | Sanofi Aventis Deutschland | Apparatus for sampling body fluid and detecting analyte |
WO2006001797A1 (en) | 2004-06-14 | 2006-01-05 | Pelikan Technologies, Inc. | Low pain penetrating |
JP2007506946A (en) * | 2003-09-23 | 2007-03-22 | エピネックス・ダイアグノスティクス・インコーポレーテッド | Rapid examination of glycoalbumin |
US8282576B2 (en) | 2003-09-29 | 2012-10-09 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for an improved sample capture device |
EP1680014A4 (en) | 2003-10-14 | 2009-01-21 | Pelikan Technologies Inc | Method and apparatus for a variable user interface |
US7822454B1 (en) | 2005-01-03 | 2010-10-26 | Pelikan Technologies, Inc. | Fluid sampling device with improved analyte detecting member configuration |
EP1706026B1 (en) | 2003-12-31 | 2017-03-01 | Sanofi-Aventis Deutschland GmbH | Method and apparatus for improving fluidic flow and sample capture |
US8828203B2 (en) | 2004-05-20 | 2014-09-09 | Sanofi-Aventis Deutschland Gmbh | Printable hydrogels for biosensors |
EP1765194A4 (en) | 2004-06-03 | 2010-09-29 | Pelikan Technologies Inc | Method and apparatus for a fluid sampling device |
US8652831B2 (en) | 2004-12-30 | 2014-02-18 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for analyte measurement test time |
US7885698B2 (en) | 2006-02-28 | 2011-02-08 | Abbott Diabetes Care Inc. | Method and system for providing continuous calibration of implantable analyte sensors |
WO2009126900A1 (en) | 2008-04-11 | 2009-10-15 | Pelikan Technologies, Inc. | Method and apparatus for analyte detecting device |
MX2011003952A (en) * | 2008-10-14 | 2011-05-23 | Piramal Healtcare Ltd | Non-enzymatic electrochemical method for simultaneous determination of total hemoglobin and glycated hemoglobin. |
US20100167306A1 (en) * | 2008-12-26 | 2010-07-01 | Henry John Smith | Rapid test for glycated albumin in saliva |
US9375169B2 (en) | 2009-01-30 | 2016-06-28 | Sanofi-Aventis Deutschland Gmbh | Cam drive for managing disposable penetrating member actions with a single motor and motor and control system |
US20100213057A1 (en) | 2009-02-26 | 2010-08-26 | Benjamin Feldman | Self-Powered Analyte Sensor |
US8965476B2 (en) | 2010-04-16 | 2015-02-24 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
WO2012075258A2 (en) * | 2010-12-03 | 2012-06-07 | Abbott Point Of Care Inc. | Ratiometric immunoassay method and blood testing device |
KR20150106520A (en) * | 2014-03-12 | 2015-09-22 | 삼성전자주식회사 | Diagnostic apparatus and diagnostic system having the same |
JP6576170B2 (en) * | 2015-09-02 | 2019-09-18 | 旭化成ファーマ株式会社 | Method for measuring glycated protein using comb electrode |
WO2017145420A1 (en) * | 2016-02-25 | 2017-08-31 | パナソニックヘルスケアホールディングス株式会社 | Biosensor |
EP3887398A4 (en) * | 2018-11-29 | 2022-10-19 | Polymer Technology Systems, Inc. | Systems and methods for electrochemical point-of-care detection of hemoglobin |
WO2021016380A1 (en) * | 2019-07-22 | 2021-01-28 | Ortho-Clinical Diagnostics, Inc. | Glycated hemoglobin measurement |
WO2022115705A2 (en) | 2020-11-30 | 2022-06-02 | Enigma Biointelligence, Inc. | Non-invasive assessment of alzheimer's disease |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4820636A (en) * | 1985-02-21 | 1989-04-11 | Medisense, Inc. | Electrochemical assay for cis-diols |
US5126247A (en) * | 1988-02-26 | 1992-06-30 | Enzymatics, Inc. | Method, system and devices for the assay and detection of biochemical molecules |
EP0745843A2 (en) * | 1995-06-01 | 1996-12-04 | Lg Electronics Inc. | Electrochemical immunobiosensor |
US5609749A (en) * | 1993-12-29 | 1997-03-11 | Mochida Pharmaceutical Co., Ltd. | Electrochemical assay method with novel p-phenylenediamine compound |
US5807747A (en) * | 1989-06-13 | 1998-09-15 | Clinical Innovations Limited | Method and apparatus for determination of glycosylated protein |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE301808C (en) | ||||
US3774243A (en) | 1971-10-20 | 1973-11-27 | D Ng | Implantable power system for an artificial heart |
DE2200054C3 (en) | 1972-01-03 | 1978-09-14 | Siemens Ag, 1000 Berlin Und 8000 Muenchen | Implantable biofuel cell |
US3811950A (en) | 1972-01-26 | 1974-05-21 | R Dibella | Biochemical fuel cell and method of operating same |
US4117202A (en) | 1976-11-12 | 1978-09-26 | Beck Timothy A | Solar powered biological fuel cell |
JPS5912135B2 (en) | 1977-09-28 | 1984-03-21 | 松下電器産業株式会社 | enzyme electrode |
JPS5817427B2 (en) | 1978-12-11 | 1983-04-07 | 松下電器産業株式会社 | enzyme electrode |
JPS5712359A (en) | 1980-06-26 | 1982-01-22 | Matsushita Electric Ind Co Ltd | Enzyme electrode |
US4490464A (en) | 1981-04-08 | 1984-12-25 | Gorton Lo G | Electrode for the electrochemical regeneration of coenzyme, a method of making said electrode, and the use thereof |
US4431004A (en) | 1981-10-27 | 1984-02-14 | Bessman Samuel P | Implantable glucose sensor |
US4581336A (en) | 1982-04-26 | 1986-04-08 | Uop Inc. | Surface-modified electrodes |
US4820399A (en) | 1984-08-31 | 1989-04-11 | Shimadzu Corporation | Enzyme electrodes |
US4806468A (en) * | 1987-02-05 | 1989-02-21 | Becton, Dickinson And Company | Measurement of glycosylated hemoglobin by immunoassay |
GB8801199D0 (en) | 1988-01-20 | 1988-02-17 | Iq Bio Ltd | Dual enzyme assay |
US5320725A (en) | 1989-08-02 | 1994-06-14 | E. Heller & Company | Electrode and method for the detection of hydrogen peroxide |
US5262035A (en) | 1989-08-02 | 1993-11-16 | E. Heller And Company | Enzyme electrodes |
US5264104A (en) | 1989-08-02 | 1993-11-23 | Gregg Brian A | Enzyme electrodes |
GB9024771D0 (en) * | 1990-11-14 | 1991-01-02 | Axis Research | Assay |
JPH04278450A (en) | 1991-03-04 | 1992-10-05 | Adam Heller | Biosensor and method for analyzing subject |
US5593852A (en) | 1993-12-02 | 1997-01-14 | Heller; Adam | Subcutaneous glucose electrode |
US5262305A (en) | 1991-03-04 | 1993-11-16 | E. Heller & Company | Interferant eliminating biosensors |
DE4126692C2 (en) | 1991-08-13 | 1995-05-11 | Bst Bio Sensor Tech Gmbh | Immunosensor device and method for determining antigens <2,000 daltons |
JP3515782B2 (en) * | 1992-03-04 | 2004-04-05 | アボット・ラボラトリーズ | Measurement of glycohemoglobin by fluorescence quenching |
DE4314417A1 (en) | 1993-05-03 | 1994-11-10 | Byk Gulden Italia Spa | Biosensor |
US5837546A (en) | 1993-08-24 | 1998-11-17 | Metrika, Inc. | Electronic assay device and method |
DE4344646A1 (en) | 1993-12-24 | 1995-06-29 | Frieder Prof Dr Scheller | Device for a competitive immuno-assay for the detection of hapten(s) |
US5804401A (en) | 1995-01-09 | 1998-09-08 | Board Of Trustees Operating Michigan State University | Device for detecting oxygen with oxidase |
US5651869A (en) | 1995-02-28 | 1997-07-29 | Matsushita Electric Industrial Co., Ltd. | Biosensor |
US5972199A (en) | 1995-10-11 | 1999-10-26 | E. Heller & Company | Electrochemical analyte sensors using thermostable peroxidase |
US5665222A (en) | 1995-10-11 | 1997-09-09 | E. Heller & Company | Soybean peroxidase electrochemical sensor |
US5639672A (en) | 1995-10-16 | 1997-06-17 | Lxn Corporation | Electrochemical determination of fructosamine |
US5888787A (en) | 1996-07-02 | 1999-03-30 | North Carolina State University | Selective enzymatic oxidation of aromatic methyl groups to aldehydes by oxygen in the presence of a laccase-mediator catalyst |
DE69809391T2 (en) | 1997-02-06 | 2003-07-10 | Therasense Inc | SMALL VOLUME SENSOR FOR IN-VITRO DETERMINATION |
US6054039A (en) | 1997-08-18 | 2000-04-25 | Shieh; Paul | Determination of glycoprotein and glycosylated hemoglobin in blood |
US5906921A (en) | 1997-09-29 | 1999-05-25 | Matsushita Electric Industrial Co., Ltd. | Biosensor and method for quantitative measurement of a substrate using the same |
US6174734B1 (en) | 1997-10-24 | 2001-01-16 | Abbott Laboratories | Measurement of glycated hemoglobin |
US6134461A (en) | 1998-03-04 | 2000-10-17 | E. Heller & Company | Electrochemical analyte |
US6103033A (en) | 1998-03-04 | 2000-08-15 | Therasense, Inc. | Process for producing an electrochemical biosensor |
US6175752B1 (en) | 1998-04-30 | 2001-01-16 | Therasense, Inc. | Analyte monitoring device and methods of use |
US6294062B1 (en) | 1998-06-01 | 2001-09-25 | Roche Diagnostics Corporation | Method and device for electrochemical immunoassay of multiple analytes |
US6294281B1 (en) | 1998-06-17 | 2001-09-25 | Therasense, Inc. | Biological fuel cell and method |
US6500571B2 (en) | 1998-08-19 | 2002-12-31 | Powerzyme, Inc. | Enzymatic fuel cell |
DE19843094A1 (en) | 1998-09-21 | 2000-03-23 | Roche Diagnostics Gmbh | Method for the determination of glycated hemoglobin |
US6338790B1 (en) | 1998-10-08 | 2002-01-15 | Therasense, Inc. | Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator |
DE60029127T2 (en) | 1999-11-16 | 2007-05-31 | Matsushita Electric Industrial Co., Ltd., Kadoma | BIOSENSOR |
ES2238254T3 (en) | 1999-12-27 | 2005-09-01 | Matsushita Electric Industrial Co., Ltd. | BIOSENSOR |
JP2001201479A (en) | 2000-01-21 | 2001-07-27 | Matsushita Electric Ind Co Ltd | Biosensor |
AU2001263022A1 (en) | 2000-05-12 | 2001-11-26 | Therasense, Inc. | Electrodes with multilayer membranes and methods of using and making the electrodes |
SG140463A1 (en) | 2000-07-14 | 2008-03-28 | Lifescan Inc | Electrochemical method for measuring chemical reaction rates |
JP4177662B2 (en) | 2000-07-24 | 2008-11-05 | 松下電器産業株式会社 | Biosensor |
US7005273B2 (en) | 2001-05-16 | 2006-02-28 | Therasense, Inc. | Method for the determination of glycated hemoglobin |
US6766817B2 (en) | 2001-07-25 | 2004-07-27 | Tubarc Technologies, Llc | Fluid conduction utilizing a reversible unsaturated siphon with tubarc porosity action |
US7368190B2 (en) | 2002-05-02 | 2008-05-06 | Abbott Diabetes Care Inc. | Miniature biological fuel cell that is operational under physiological conditions, and associated devices and methods |
EP1403722B8 (en) | 2002-09-24 | 2005-10-05 | Ricoh Company, Ltd. | Electrophotographic photoconductor, electrophotography method, electrophotographic apparatus, eletrophotographic apparatus process cartridge using a specific outermost surface layer coating solution for the photoconductor |
-
2002
- 2002-05-14 US US10/146,577 patent/US7005273B2/en not_active Expired - Lifetime
- 2002-05-15 WO PCT/US2002/015706 patent/WO2002093152A1/en not_active Application Discontinuation
-
2005
- 2005-12-06 US US11/296,183 patent/US8206563B2/en not_active Expired - Fee Related
-
2012
- 2012-05-21 US US13/476,625 patent/US8460525B2/en not_active Expired - Lifetime
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4820636A (en) * | 1985-02-21 | 1989-04-11 | Medisense, Inc. | Electrochemical assay for cis-diols |
US5126247A (en) * | 1988-02-26 | 1992-06-30 | Enzymatics, Inc. | Method, system and devices for the assay and detection of biochemical molecules |
US5807747A (en) * | 1989-06-13 | 1998-09-15 | Clinical Innovations Limited | Method and apparatus for determination of glycosylated protein |
US5609749A (en) * | 1993-12-29 | 1997-03-11 | Mochida Pharmaceutical Co., Ltd. | Electrochemical assay method with novel p-phenylenediamine compound |
EP0745843A2 (en) * | 1995-06-01 | 1996-12-04 | Lg Electronics Inc. | Electrochemical immunobiosensor |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0526752A (en) * | 1991-07-16 | 1993-02-02 | Oval Corp | Manufacture of pressure sensor |
US9410915B2 (en) | 2004-06-18 | 2016-08-09 | Roche Operations Ltd. | System and method for quality assurance of a biosensor test strip |
JP2014523235A (en) * | 2011-05-24 | 2014-09-11 | サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィク | Bilirubin oxidase from rice blast fungus and use thereof |
Also Published As
Publication number | Publication date |
---|---|
US8460525B2 (en) | 2013-06-11 |
US7005273B2 (en) | 2006-02-28 |
US8206563B2 (en) | 2012-06-26 |
US20020172992A1 (en) | 2002-11-21 |
US20120305395A1 (en) | 2012-12-06 |
US20060205029A1 (en) | 2006-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7005273B2 (en) | Method for the determination of glycated hemoglobin | |
EP0194084B1 (en) | Electrochemical assay for cis-diols | |
EP0216577B1 (en) | Sensor | |
EP2462239B1 (en) | Fructosyl peptidyl oxidase and sensor for assaying a glycated protein | |
AU642879B2 (en) | Glycosylated haemoglobin assay | |
Pundir et al. | Determination of glycated hemoglobin with special emphasis on biosensing methods | |
CN104105968B (en) | For using enzyme process, the hemolyzing reagent composition of quantitative test is carried out to glycosylated hemoglobin | |
McLemore et al. | Rapid automated determination of lipid hydroperoxide concentrations and total antioxidant status of serum samples from patients infected with HIV: elevated lipid hydroperoxide concentrations and depleted total antioxidant capacity of serum samples | |
JPWO2007094354A1 (en) | Hemoglobin A1c sensor | |
US4438204A (en) | Determination of glycosilated hemoglobin | |
EP0455225B1 (en) | Method for measuring the percentage of glycation of a particular protein | |
WO1994028405A1 (en) | Electrochemical metal analysis | |
EP0407860B1 (en) | Lithium salts as red blood cell lysing and hemoglobin denaturing reagents | |
JP4847668B2 (en) | Method for detecting glycated albumin | |
Sun et al. | Electrocatalytic reduction of hemoglobin at a chemically modified electrode containing riboflavin | |
CN111751523B (en) | Biochemical index detection device based on micro-fluidic chip and smart phone | |
US20030186330A1 (en) | Enzyme-mimicking polymers | |
JPS585190A (en) | Production of purified animal origin uricase active substance used in measuring uric acid in sample | |
Hayashi et al. | Heterogeneity of urinary albumin from diabetic patients | |
US5281393A (en) | Multilayered device containing a polymer-copper complex to control interference of biological substances in colorimetric test systems | |
JP3181390B2 (en) | Method for measuring protein saccharification ratio | |
Little et al. | and other circulating glycated proteins | |
Vigneshwaran et al. | Fluorescence and biochemical characterization of glycated hemoglobin | |
Altura et al. | Vascular diseases and ionized magnesium | |
Whitlow et al. | Potential bilirubin interference with the Technicon SMAC alkaline phosphatase activity measurement. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |